Published 12 days ago • loading... • Updated 12 days ago

CellFE and Made Scientific Announce Strategic Collaboration to Advance Non-viral Gene Editing for T Cell Therapies

On May 13, 2025, CellFE and Made Scientific announced a strategic collaboration in Alameda, California, and Princeton, New Jersey to advance T cell therapies.
The collaboration formed to generate pilot data on CellFE’s non-viral microfluidics gene editing technology by assessing two distinct workflows for activated and resting T cells.
Made Scientific has been chosen by CellFE to perform early-stage evaluations with the High Volume Cyva™ System, aiming to validate the scalability, durability, and clinical-level effectiveness of CellFE’s technology platform.
CellFE CEO Alla Zamarayeva said their collaboration will establish a new benchmark in T cell therapy manufacturing by combining breakthrough microfluidics and world-class CDMO services.
The partnership aims to address key industry challenges, accelerate advanced cell therapy delivery, and will share pilot program results with the community by October 2025.

Insights by Ground AI

Does this summary seem wrong?

14 Articles

All

Left

Center

Right

Albany Democrat Herald

+13 Reposted by 13 other sources

Center

CellFE and Made Scientific Announce Strategic Collaboration to Advance Non-viral Gene Editing for T Cell Therapies

ALAMEDA, Calif. and PRINCETON, N.J., May 13, 2025 /PRNewswire/ -- CellFE, a leader in microfluidics-based cell engineering, and Made Scientific, a leading cell therapy contract development and manufacturing organization (CDMO), today announced a strategic collaboration to generate pilot data on…

12 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year